QURE

11 atoms · 跨 4 天 · 首见 2026-05-07 · 最近 2026-06-24

三色: 🟦 fact 4 · 🟥 take 7 · stance ▲8/▼0/◆3

来源: X 11

时态: fresh:9 · aging:2

标签: 好观点:5 · 好数字:4 · 好信源:3 · 好思考:1

叙事 (narrative) (5)

• 2026-06-20 · 目标价调整
  uniQure N.V. 目标价变动: $28.00 至 $71.00 (+153.6%)
  tags: 好数字 · → daily
  value: qty=$28.00 至 $71.00 · direction=上调
• 2026-06-17 · Barclays评级
  Barclays reiterates Equalweight on uniQure
  tags: 好信源 · → daily
  value: direction=Equalweight
• 2026-06-17 · Barclays目标价
  maintains PT at $25
  tags: 好数字 · → daily
  value: qty=$25
• 2026-06-17 · Stifel 评级买入
  Stifel reiterates Buy on uniQure
  tags: 好观点 · → daily
• 2026-05-07 [老化中] · 期权持仓标的及执行价
  QURE June 30/35 calls
  tags: 好思考 · → daily

预测 (forecast) (2)

• 2026-06-17 · AMT-130 加速批准概率预期
  modeling a >50% chance of accelerated approval and 2027 launch
  tags: 好数字·好观点 · → daily
  value: qty=>50% · date=当前
• 2026-06-17 · AMT-130 上市时间预期
  modeling a >50% chance of accelerated approval and 2027 launch
  tags: 好观点 · → daily
  value: date=2027

立场 (position) (1)

• 2026-06-17 [老化中] · Stifel 目标价上调
  raises PT to $71 from $28
  tags: 好数字·好观点 · → daily
  value: qty=$71 · date=当前

事实 (fact) (3)

• 2026-06-17 · FDA 反馈支持使用 3年 Phase I/II AMT-130 数据作为 BLA 主要基础
  FDA feedback supports using 3-year Phase I/II AMT-130 data as the primary basis for a BLA seeking accelerated approval in Huntington’s disease
  tags: 好信源 · → daily
  value: date=2026-06-17
• 2026-06-17 · BLA 计划于 2026 年 Q3 提交
  BLA planned for Q3 2026
  tags: 好信源 · → daily
  value: date=2026 Q3
• 2026-06-24 · AMT-130临床试验结果
  A symptomatic HD patient went from being 'no longer able to work' ('on medical disability') 6 yrs ago (before enrolling in AMT-130 trial), to being stabilized & improved, able to exercise, work full time, and got married.
  tags: 好观点 · → daily
  value: qty=symptomatic HD patient went from being no longer able to work to stabilized & improved, able to exercise, work full time, and got married · date=6 yrs after enrollment

时间轴 (近 20)

• 2026-06-24 · fact · AMT-130临床试验结果 · → daily
• 2026-06-20 · narrative · 目标价调整 · → daily
• 2026-06-17 · fact · FDA 反馈支持使用 3年 Phase I/II AMT-130 数据作为 BLA 主要基础 · → daily
• 2026-06-17 · fact · BLA 计划于 2026 年 Q3 提交 · → daily
• 2026-06-17 · narrative · Barclays评级 · → daily
• 2026-06-17 · narrative · Barclays目标价 · → daily
• 2026-06-17 · narrative · Stifel 评级买入 · → daily
• 2026-06-17 · position · Stifel 目标价上调 · → daily
• 2026-06-17 · forecast · AMT-130 加速批准概率预期 · → daily
• 2026-06-17 · forecast · AMT-130 上市时间预期 · → daily
• 2026-05-07 · narrative · 期权持仓标的及执行价 · → daily

← 实体目录 · 系统日志